nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

03.05.2019 | Retinal Disorders

OCT angiography-based monitoring of neovascular regression on fibrovascular membrane after preoperative intravitreal conbercept injection

verfasst von: Zizhong Hu, Yun Su, Ping Xie, Lu Chen, Jiangdong Ji, Ting Feng, Shaowei Wu, Kang Liang, Qinghuai Liu

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To quantify the preoperative neovascular change pattern on the fibrovascular membrane (FVM) within 7 days after intravitreal injection of conbercept (IVC) using optical coherence tomography angiography (OCTA) in proliferative diabetic retinopathy (PDR).

Methods

Prospective, observational study of PDR patients with visible FVM receiving or not receiving IVC. Neovascular changes were assessed by OCTA pre-IVC and 1, 3, 5, and 7 days post-IVC. Vessel skeleton density (SD) and vessel density (VD) were quantified by an intensity-based optical microangiography algorithm. The interclass correlation coefficient (ICC) was calculated to assess the agreement between measurements. The SD and VD were compared between follow-ups using repeated-measures analysis in the IVC group.

Results

The ICC was 0.992 (95% confidence interval [CI]: 0.982–0.996) for SD and 0.926 (95% CI: 0.838–0.912) for VD of neovascularization. The neovascularization on FVM significantly regressed in the IVC group (n = 16) compared with no IVC (n = 8) (p = 0.001 for SD and p < 0.001 for VD). The comparisons between consecutive follow-ups showed a statistically significant reduction in SD and VD at 1 and 3 days post-IVC. However, from day 3 onward, the SD and VD remained unchanged. There was no development or progression of tractional retinal detachment within the 7-day period after IVC.

Conclusion

OCTA–based quantification of the neovascularization on FVM in PDR is feasible, with high inter-reader agreement. The regression of neovascularization reaches a plateau 3 days after IVC.

Clinical Trial Registration

This trial is registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn, registration number ChiCTR-IPR-17014160).

Nur mit Berechtigung zugänglich

Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124–136. https://doi.org/10.1016/S0140-6736(09)62124-3 CrossRefPubMed

Adamis AP, Miller JW, Bernal M-T, D'Amico DJ, Folkman J, Yeo T-K, Yeo K-T (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450. https://doi.org/10.1016/S0002-9394(14)75794-0 CrossRefPubMed

Liu L, Tham YC, Cheng CY (2017) Intravitreal aflibercept for proliferative diabetic retinopathy. Lancet 390:2140–2141. https://doi.org/10.1016/s0140-6736(17)32426-1 CrossRefPubMed

Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695–1705.e1696. https://doi.org/10.1016/j.ophtha.2006.05.064 CrossRefPubMed

Su L, Ren X, Wei H, Zhao L, Zhang X, Liu J, Su C, Tan L, Li X (2016) Intravitreal conbercept (KH902) for surgical treatment of severe proliferative diabetic retinopathy. Retina 36:938–943. https://doi.org/10.1097/iae.0000000000000900 CrossRefPubMed

Smith JM, Steel DH (2015) Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev Cd008214. https://doi.org/10.1002/14651858.CD008214.pub3

Zhang ZH, Liu HY, Hernandez-Da Mota SE, Romano MR, Falavarjani KG, Ahmadieh H, Xu X, Liu K (2013) Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. Am J Ophthalmol 156:106–115.e102. https://doi.org/10.1016/j.ajo.2013.02.008 CrossRefPubMed

Zhao XY, Xia S, Chen YX (2017) Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2017-311344

Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, Luo D, Ke X (2014) Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121:1740–1747. https://doi.org/10.1016/j.ophtha.2014.03.026 CrossRefPubMed

10.

Li F, Sun M, Guo J, Ma A, Zhao B (2017) Comparison of conbercept with ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion. Curr Eye Res 42:1174–1178. https://doi.org/10.1080/02713683.2017.1285943 CrossRefPubMed

11.

Li F, Zhang L, Wang Y, Xu W, Jiao W, Ma A, Zhao B (2017) One-year outcome of Conbercept therapy for diabetic macular edema. Curr Eye Res 1–6. https://doi.org/10.1080/02713683.2017.1379542

12.

Yang X, Xu J (2016) A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy 2016:2473234. https://doi.org/10.1155/2016/2473234

13.

Arevalo JF, Maia M, Flynn H, Saravia M, Avery RL, Wu L, Farah ME, Pieramici DJ, Berrocal MH, Sanchez JG (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216CrossRefPubMed

14.

Hu Z, Liu Q, Paulus YM (2016) New Frontiers in retinal imaging. Int Ophthalmic Res 2:148–158CrossRef

15.

Gupta A, Bansal R, Gupta V, Dogra MR (2012) Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab. Int Ophthalmol 32:135–144. https://doi.org/10.1007/s10792-012-9541-5 CrossRefPubMed

16.

Erdol H, Turk A, Akyol N, Imamoglu HI (2010) The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina 30:570–577. https://doi.org/10.1097/IAE.0b013e3181bf5ff0 CrossRefPubMed

17.

Abdelhakim MA, Macky TA, Mansour KA, Mortada HA (2011) Bevacizumab (Avastin) as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Ophthalmic Res 45:23–30. https://doi.org/10.1159/000314721 CrossRefPubMed

18.

Hu Z, Ding Y, Zheng X, Yuan S, Li J, Xie P, Liu Q (2018) Thin rigid contact Lens used in vitreous-retinal surgery for corneal protection: a randomized controlled trial. Eye Contact Lens. https://doi.org/10.1097/ICL.0000000000000491

19.

Jia Y, Tan O, Tokayer J, Potsaid B, Wang Y, Liu JJ, Kraus MF, Subhash H, Fujimoto JG, Hornegger J (2012) Split-spectrum amplitude-decorrelation angiography with optical coherence tomography. Opt Express 20:4710–4725. https://doi.org/10.1364/OE.20.004710 CrossRefPubMedPubMedCentral

20.

Amoroso F, Miere A, Semoun O, Jung C, Capuano V, Souied EH (2017) Optical coherence tomography angiography reproducibility of lesion size measurements in neovascular age-related macular degeneration (AMD). Br J Ophthalmol bjophthalmol-2017-310569. https://doi.org/10.1136/bjophthalmol-2017-310569

21.

Venugopal JP, Rao HL, Weinreb RN, Pradhan ZS, Dasari S, Riyazuddin M, Puttiah NK, Rao DA, Devi S, Mansouri K (2017) Repeatability of vessel density measurements of optical coherence tomography angiography in normal and glaucoma eyes. Br J Ophthalmol bjophthalmol-2017-310637. https://doi.org/10.1136/bjophthalmol-2017-310637

22.

Gao SS, Liu L, Bailey ST, Flaxel CJ, Huang D, Li D, Jia Y (2016) Quantification of choroidal neovascularization vessel length using optical coherence tomography angiography. J Biomed Opt 21:076010–076010. https://doi.org/10.1117/1.JBO.21.7.076010 CrossRefPubMedCentral

23.

Rosen RB, Andrade Romo JS, Krawitz BD, Mo S, Fawzi AA, Linderman R, Carroll J, Pinhas A, Chui TYP (2019) Earliest evidence of preclinical diabetic retinopathy revealed using OCT angiography (OCTA) perfused capillary density. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2019.01.012

24.

Kaizu Y, Nakao S, Sekiryu H, Wada I, Yamaguchi M, Hisatomi T, Ikeda Y, Kishimoto J, Sonoda KH (2018) Retinal flow density by optical coherence tomography angiography is useful for detection of nonperfused areas in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 256:2275–2282. https://doi.org/10.1007/s00417-018-4122-6 CrossRefPubMed

25.

Dodo Y, Suzuma K, Ishihara K, Yoshitake S, Fujimoto M, Yoshitake T, Miwa Y, Murakami T (2017) Clinical relevance of reduced decorrelation signals in the diabetic inner choroid on optical coherence tomography angiography. Sci Rep 7:5227. https://doi.org/10.1038/s41598-017-05663-9 CrossRefPubMedPubMedCentral

26.

Onishi AC, Nesper PL, Roberts PK, Moharram GA, Chai H, Liu L, Jampol LM, Fawzi AA (2018) Importance of considering the middle capillary plexus on OCT angiography in diabetic retinopathy. Invest Ophthalmol Vis Sci 59:2167–2176. https://doi.org/10.1167/iovs.17-23304 CrossRefPubMedPubMedCentral

27.

Lu Y, Simonett JM, Wang J, Zhang M, Hwang T, Hagag AM, Huang D, Li D, Jia Y (2018) Evaluation of automatically quantified foveal avascular zone metrics for diagnosis of diabetic retinopathy using optical coherence tomography angiography. Invest Ophthalmol Vis Sci 59:2212–2221. https://doi.org/10.1167/iovs.17-23498 CrossRefPubMedPubMedCentral

28.

Sawada O, Ichiyama Y, Obata S, Ito Y, Kakinoki M, Sawada T, Saishin Y, Ohji M (2018) Comparison between wide-angle OCT angiography and ultra-wide field fluorescein angiography for detecting non-perfusion areas and retinal neovascularization in eyes with diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 256:1275–1280. https://doi.org/10.1007/s00417-018-3992-y CrossRefPubMed

29.

Schaal KB, Munk MR, Wyssmueller I, Berger LE, Zinkernagel MS, Wolf S (2019) Vascular abnormalities in diabetic retinopathy assessed with swept-source optical coherence tomography angiography widefield imaging. Retina 39:79–87. https://doi.org/10.1097/iae.0000000000001938 CrossRefPubMed

30.

Singh A, Agarwal A, Mahajan S, Karkhur S, Singh R, Bansal R, Dogra MR, Gupta V (2017) Morphological differences between optic disc collaterals and neovascularization on optical coherence tomography angiography. Graefes Arch Clin Exp Ophthalmol 255:753–759. https://doi.org/10.1007/s00417-016-3565-x CrossRefPubMed

31.

Pan J, Chen D, Yang X, Zou R, Zhao K, Cheng D, Huang S, Zhou T, Yang Y, Chen F (2018) Characteristics of neovascularization in early stages of proliferative diabetic retinopathy by optical coherence tomography angiography. Am J Ophthalmol 192:146–156. https://doi.org/10.1016/j.ajo.2018.05.018 CrossRefPubMed

32.

Zhang X, Wu C, Zhou LJ, Dai RP (2018) Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal conbercept injections. Sci Rep 8:3972. https://doi.org/10.1038/s41598-018-22363-0 CrossRefPubMedPubMedCentral

33.

Lee J, Moon BG, Cho AR, Yoon YH (2016) Optical coherence tomography angiography of DME and its association with anti-VEGF treatment response. Ophthalmology 123:2368–2375. https://doi.org/10.1016/j.ophtha.2016.07.010 CrossRefPubMed

34.

Ghasemi Falavarjani K, Iafe NA, Hubschman JP, Tsui I, Sadda SR, Sarraf D (2017) Optical coherence tomography angiography analysis of the foveal avascular zone and macular vessel density after anti-VEGF therapy in eyes with diabetic macular edema and retinal vein occlusion. Invest Ophthalmol Vis Sci 58:30–34. https://doi.org/10.1167/iovs.16-20579 CrossRefPubMed

35.

Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G (2008) Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 246:837–842. https://doi.org/10.1007/s00417-008-0774-y

36.

Kohno R-I, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, Miyazaki M, Hisatomi T, Ikeda Y, Aiello LP (2010) Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol 150:223–229. https://doi.org/10.1016/j.ajo.2010.03.016

37.

Manabe A, Shimada H, Hattori T, Nakashizuka H, Yuzawa M (2015) Randomized controlled study of intravitreal bevacizumab 0.16 mg injected one day before surgery for proliferative diabetic retinopathy. Retina (Philadelphia, Pa) 35:1800–1807. https://doi.org/10.1097/iae.0000000000000577

38.

Di Lauro R, De Ruggiero P, Di Lauro R, Di Lauro MT, Romano MR (2010) Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248:785–791. https://doi.org/10.1007/s00417-010-1303-3

39.

El-Sabagh HA, Abdelghaffar W, Labib AM, Mateo C, Hashem TM, Al-Tamimi DM, Selim AA (2011) Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology 118:636–641. https://doi.org/10.1016/j.ophtha.2010.08.038

40.

Da R Lucena D, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL, Jorge R (2009) Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 93:688–691. https://doi.org/10.1136/bjo.2008.151233

41.

Castillo J, Aleman I, Rush SW, Rush RB (2017) Preoperative bevacizumab administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a randomized and controlled trial comparing interval variation. Am J Ophthalmol 183:1–10. https://doi.org/10.1016/j.ajo.2017.08.013

42.

Farahvash M-S, Majidi AR, Roohipoor R, Ghassemi F (2011) Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage. Retina (Philadelphia, Pa) 31:1254–1260. https://doi.org/10.1097/IAE.0b013e31820a68e5

43.

Spaide RF, Fujimoto JG, Waheed NK (2015) Image artifacts in optical coherence tomography angiography. Retina (Philadelphia, Pa) 35:2163–2180. https://doi.org/10.1097/IAE.0000000000000765

44.

Hirano T, Kakihara S, Toriyama Y, Nittala MG, Murata T, Sadda S (2017) Wide-field en face swept-source optical coherence tomography angiography using extended field imaging in diabetic retinopathy. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2017-311358

Titel: OCT angiography-based monitoring of neovascular regression on fibrovascular membrane after preoperative intravitreal conbercept injection
verfasst von: Zizhong Hu
Yun Su
Ping Xie
Lu Chen
Jiangdong Ji
Ting Feng
Shaowei Wu
Kang Liang
Qinghuai Liu
Publikationsdatum: 03.05.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 8/2019
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-019-04315-0

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

OCT angiography-based monitoring of neovascular regression on fibrovascular membrane after preoperative intravitreal conbercept injection

Abstract

Purpose

Methods

Results

Conclusion

Clinical Trial Registration

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Clinical Trial Registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

The influence of visual field position induced by a retinal prosthesis simulator on mobility

Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis

The standardized definition of high myopia

Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration

Retraction Note to: A comparison of risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese patients

Open globe trauma in a military hospital: a review of the Ocular Trauma Score to help predict enucleation or evisceration

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde